GH Research (NASDAQ:GHRS) Price Target Raised to $32.00 at Stifel Nicolaus

GH Research (NASDAQ:GHRS - Free Report) had its price objective increased by Stifel Nicolaus from $18.00 to $32.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald started coverage on GH Research in a research note on Thursday, February 13th. They set an "overweight" rating and a $14.00 price target on the stock. Canaccord Genuity Group lowered their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, November 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $30.60.

GH Research Stock Down 9.1 %

GHRS traded down $0.92 during midday trading on Thursday, reaching $9.21. 610,681 shares of the company's stock were exchanged, compared to its average volume of 640,422. The firm has a market capitalization of $479.18 million, a price-to-earnings ratio of -11.66 and a beta of 0.93. GH Research has a one year low of $6.00 and a one year high of $20.50. The business has a 50-day simple moving average of $10.51 and a two-hundred day simple moving average of $9.19.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. As a group, research analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new stake in GH Research in the 4th quarter valued at $44,000. Two Sigma Investments LP acquired a new position in GH Research in the 4th quarter valued at $117,000. Millennium Management LLC acquired a new position in GH Research in the fourth quarter valued at about $145,000. AdvisorShares Investments LLC lifted its holdings in shares of GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after acquiring an additional 4,806 shares during the period. Finally, Northern Trust Corp lifted its stake in GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).